FDA Denies Approval of Regeneron’s Linvoseltamab for Multiple Myeloma, Cites Third-Party Manufacturing Issues

The regulator’s Complete Response Letter flagged problems at a third-party fill/finish site, which Regeneron says it has already addressed. The manufacturing facility is currently awaiting reinspection.